Korro Bio (KRRO) Total Liabilities (2018 - 2026)
Korro Bio's (KRRO) quarterly Total Liabilities came in at $64.0 million in Q1 2026, up 1.17% YoY from $63.2 million in Q1 2025, and up 3.1% on a QoQ basis from $62.1 million in Q4 2025.
Korro Bio (KRRO) Total Liabilities (2018 - 2026) Analysis & Trends
Korro Bio (KRRO) has 9 years of Total Liabilities data on file, last reported at $64.0 million in Q1 2026.
- Quarterly Total Liabilities rose 1.17% year-over-year to $64.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $64.0 million (up 1.17% YoY) and the FY2025 annual result came in at $62.1 million, down 5.71% from the prior year.
- Total Liabilities grew to $64.0 million in Q1 2026, from $62.1 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $65.8 million in Q4 2024 to a low of $8.9 million in Q4 2022.
- A 5-year average of $50.4 million and a median of $53.8 million in 2022 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2022 — Total Liabilities tumbled 83.66% — and 2024, when it surged 564.91%.
- Tracing KRRO's Total Liabilities over 5 years: stood at $8.9 million in 2022, then surged by 480.83% to $51.8 million in 2023, then gained by 27.19% to $65.8 million in 2024, then fell by 5.71% to $62.1 million in 2025, then advanced by 3.1% to $64.0 million in 2026.
- The last three Total Liabilities figures came in at $64.0 million (Q1 2026), $62.1 million (Q4 2025), and $62.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | Korro Bio | 228.60 Mn | 113.56 Mn | - | 60.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 60.22 Mn |
| Mar 31, 2026 | 63.99 Mn |
| Dec 31, 2025 | 62.07 Mn |
| Sep 30, 2025 | 62.52 Mn |
| Jun 30, 2025 | 65.32 Mn |
| Mar 31, 2025 | 63.25 Mn |
| Dec 31, 2024 | 65.83 Mn |
| Sep 30, 2024 | 63.91 Mn |
| Jun 30, 2024 | 51.51 Mn |
| Mar 31, 2024 | 46.63 Mn |
| Dec 31, 2023 | 51.75 Mn |
| Sep 30, 2023 | 9.61 Mn |
| Jun 30, 2023 | 33.98 Mn |
| Mar 31, 2023 | 48.25 Mn |
| Dec 31, 2022 | 8.91 Mn |
| Sep 30, 2022 | 54.04 Mn |
| Jun 30, 2022 | 53.81 Mn |
| Mar 31, 2022 | 52.27 Mn |
| Dec 31, 2021 | 54.53 Mn |
| Sep 30, 2021 | 55.07 Mn |